GSK plc - Jun 16, 2021 Form 3 Insider Report for 23andMe Holding Co. (ME)

Role
10%+ Owner
Signature
/s/ Victoria Whyte, Authorized Signatory, GSK plc
Stock symbol
ME
Transactions as of
Jun 16, 2021
Transactions value $
$0
Form type
3
Date filed
11/4/2022, 04:11 PM
Previous filing
May 24, 2021
Next filing
Jun 23, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ME Class B Common Stock Jun 16, 2021 Class A Common Stock 39.7M $0.00 See Footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the post Share Conversion Ratio (which is equal to 2.293698) number shares of Class B common stock, par value $0.0001, of 23andMe Holding Co. (the "Issuer"), acquired due to the completion of the merger between Issuer (f/k/a VG Acquisition Corp. ("VGAC")), Chrome Merger Sub, Inc., a Delaware corporation and wholly owned direct subsidiary of VGAC ("Merger Sub"), and 23andMe, Inc., a Delaware corporation ("23andMe"), (the "Business Combination") pursuant to the Agreement and Plan of Merger, dated as of February 4, 2021.
F2 The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GSK plc (the "Reporting Person").
F3 Shares of Class B Common Stock, which are not registered under the Securities Exchange Act of 1934, as amended, are convertible into shares of Class A Common Stock on a share-for-share basis at any time at the option of the holder. The Class B ordinary shares have no expiration date.